Nurevo home
Menu

Solutions

Nurevo is being designed for organisations that need a low-burden way to prioritise who should be seen sooner.

Who it is for

  1. 01

    Health systems and memory services

    Nurevo is being designed so health systems and memory services can prioritise referrals.

  2. 02

    Primary care

    Nurevo is being designed for primary care, as a low-burden conversation that can offer an early signal before a specialist referral.

  3. 03

    Care homes and community organisations

    Nurevo is being designed for care homes and community organisations, where a short conversation on a phone or laptop can be offered in the place where the person already is.

  4. 04

    Pharmaceutical companies and research partners

    Nurevo is being designed for pharmaceutical companies and contract research organisations, to support recruitment and stratification for early-stage trials.

Nurevo is in development and not yet available for clinical use. We welcome conversations about future pilots and research.

Talk to us

Research and responsible AI

How Nurevo is being developed: what the system is for, what goes in and out, its limits, and the steps still to come.

Version
Prototype
Last reviewed
Status
Nurevo is at prototype stage and preparing clinical validation.

Nurevo is at pre-seed stage. There is a working prototype of the data pipeline. Nurevo is preparing clinical validation.

System card

  • Intended use

    Nurevo is a screening and triage tool. A short conversation produces an explainable risk score, helping clinicians decide who needs specialist assessment first.

  • Intended population

    Nurevo is designed for diverse, multilingual populations. Screening is not built around one language or culture.

  • Inputs

    A short guided conversation on a phone or laptop is analysed across speech timing and voice, language, facial movement, and background information.

  • Output

    The output is one explainable risk score. It shows which signals contributed most.

  • Limitations

    Nurevo is at prototype stage and preparing clinical validation. No performance figures are published. It is not a diagnostic device, and it is not currently available for clinical use.

  • Human oversight

    A clinician can see what informed the result. The score helps clinicians decide who needs specialist assessment first.

  • Fairness

    Nurevo aims to report how the screening behaves across languages, ages and sexes, so differences can be seen and addressed. No performance figures are published at this prototype stage.

Data protection

Nurevo is designing the service around consent, UK GDPR and data minimisation.

Privacy

  • Consent

    People take part by choice, and know what the conversation is used for.

  • UK GDPR

    The service is being designed to meet UK data protection law.

  • Data minimisation

    The service is designed to collect and keep the least information needed for screening.

Roadmap

Where the work stands, without dates:

  1. Completed

    Working prototype

  2. Completed

    Feasibility testing

  3. In progress

    Model development

  4. Planned

    Clinical studies

  5. Planned

    The UK pathway for software as a medical device, overseen by the MHRA

How we plan to evaluate

The evaluation plan is named here so it can be checked later. No results are published.

  • Subgroup reporting

    Report how the screening behaves across languages, age groups and sexes, side by side.

  • Comparison with specialist assessment

    Compare the risk score with the outcome of specialist assessment in registered clinical studies.

  • Clinician review of explanations

    Ask clinicians whether the signals shown as contributing most help them decide who to see sooner.

Regulatory status

Where Nurevo stands today, in plain terms, and the route it intends to follow before any clinical use.

Nurevo is a screening and triage tool in development. It is not a diagnostic device and is not currently available for clinical use.

What it is
A screening and triage tool in development
Clinical use
Not currently available
Conformity marking
None held
Regulatory clearance
None held
Intended route
UK pathway for software as a medical device, overseen by the MHRA Planned

The intended route

Nurevo intends to follow the UK pathway for software as a medical device, overseen by the MHRA. The roadmap places this pathway after model development and clinical studies. The working prototype and feasibility testing are complete. No date is set.

  1. 1

    Build the evidence

    The working prototype and feasibility testing are complete. Model development is underway, followed by registered clinical studies.

    Planned

  2. 2

    Quality and risk management

    Put a quality management system and clinical risk management in place.

    Planned

  3. 3

    Conformity assessment

    Show that the software meets UK medical device requirements.

    Planned

  4. 4

    Registration with the MHRA

    Register the device before any clinical use in the UK.

    Planned

No date is set for any step. This section will be updated as each step is reached.

Last updated